Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Down 88.9% in December

Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) saw a large drop in short interest in December. As of December 31st, there was short interest totalling 101,000 shares, a drop of 88.9% from the December 15th total of 909,800 shares. Based on an average daily trading volume, of 467,300 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on IPHA shares. Evercore ISI upgraded shares of Innate Pharma to a "strong-buy" rating in a research note on Monday, September 16th. HC Wainwright restated a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a report on Monday, December 9th.

Innate Pharma Trading Up 2.8 %

IPHA traded up $0.05 on Monday, hitting $1.82. 29,616 shares of the company's stock were exchanged, compared to its average volume of 43,231. The firm has a 50-day moving average price of $1.80 and a 200-day moving average price of $2.02. Innate Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $3.51.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.